SECOS raising cash to progress high margin bioplastic resins
Published 12-NOV-2018 11:11 A.M.
|
3 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
It has been reported that 75% of beach rubbish in Australia is made up of plastic.
That equates to some 2,651,613 pieces of debris collected from beachesand recorded in a database during 2016 and 2017.
Suffice to say, we need to clean up our act a little bit.
Of course, this isn’t just an Australian issue.
According to National Geographic every September for last 30 years, the Ocean Conservancy, has collected 300 million pounds of trash and more than 350 types of items.
For the first time in 2017,all of the top ten items retrieved were plastics, displacing glass bottles, aluminium cans, and rope that had been stalwarts on the list.
There has been a rise of companies combating this trend.
SECOS Group (ASX:SES) is at the forefront in bringing bioplastic compostable films and resins into the mainstream to replace the widespread use of traditional petroleum based plastics.
This leading global producer of eco-friendly bioplastic materials from its proprietary bio-based resin technology, is developing a world-first breathable compostable film product line to meet a presently unmet need. This higher margin biodegradable, compostable and hybrid resin can be used to make sustainable hygiene and other packaging materials.
Production of this bioplastic resin is being ramped up at SECOS’ newly acquired Malaysian plant as demand for the material rises faster than ever. The new 30,000sq ft. facility is ideally located close to Malaysia’s largest port and will assist in expanding further in the key markets of Malaysia, China and the US, where it already has strong foundations.
The plant will provide the company with additional capacity and sales to meet the growing global demand for bioplastics, which is forecast to see exceptional rates of growth over the near term.
The growth on offer in this area has seen the company adopt a strategic focus on the high margin compostable resin corner of the market, and is developing a world-first breathable compostable film product line for the hygiene and medical markets.
Already that decision is paying off.
In late October, SES provided its quarterly report for the quarter ended 30 September 2018. The company’s bioplastic resin sales were the stand-out, up 296% on the year, and is where the company anticipates continued strong growth going forward.
SECOS expects to increase its bioplastic resin sales rate sevenfold, from the current annual revenue run-rate of $1 million, to more than $7 million by June 2019, supported by a strong forward order pipeline from existing customers.
Further to this, positive feedback from prospective packaging customers in the US, Europe and Asia provides confidence in continued growth in SES’s global bioplastic resin sales.
The company is currently undertaking a Rights Issue to raise up to $2.7 million, offering eligible shareholders one fully paid ordinary share for every six shares already held. Additionally, a private placement of 15,179,597 new fully paid ordinary shares to institutional and sophisticated investors, and 4,516,130 new fully paid ordinary shares is to be issued to directors of the company, subject to shareholder approval.
The rights issue ends Tuesday 13 November.
All up, SES expect to raise up to $4.0 million in total before costs, which will be used to fund working capital requirements to expand its bioplastics operations in Malaysia, its bioplastics sales in the US, as well improving efficiencies in the films business.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.